Аннотация
Следовые амины (СА) представляют собой семейство эндогенных соединений структурно сходных с классическими биогенными аминами, которые могут быть вовлечены в патогенез ряда нейропсихиатрических заболеваний. Одним из самых изученных и перспективных членов семейства TAARs является TAAR1 рецептор. Целью данного исследования явилось изучение изменения сенсорного гейтинга у свободно подвижных мышей нокаутных по ТААR1 рецептору в хроническом эксперименте. Исследование СГ проводилось в парадигме парных щелчков, показатель СГ высчитывался как абсолютное значение, посчитанное методом вычитания амплитуды ответа на второй стимул из амплитуды ответа на первый стимул в паре (С1-С2) и как относительный показатель СГ, посчитанный методом деления амплитуды С2 на амплитуду ответа на С1 (С2/С1). В результате было обнаружено значительное снижение амплитуды компонента N40 у мышей нокаутных по TAAR1 гену по сравнению с мышами дикого типа. Кроме того абсолютное значение сенсорного гейтинга, посчитанное методом (С1-С2), также было снижено, но относительный показатель сенсорного гейтинга, посчитанный методом (С1/С2), оставался неизменным. Таким образом, полученные данные указывают на участие TAAR1 в генерации слуховых вызванных потенциалов и на потенциальное вовлечение системы следовых аминов в процесс дозирования и фильтрации сенсорной информации.
Литература
Millan MJ, Rivet JM, Gobert A (2016) The frontal cortex as a network hub controlling mood and cognition: Probing its neurochemical substrates for improved therapy of psychiatric and neurological disorders. J Psychopharmacol 30:1099–1128. https://doi.org/10.1177/0269881116672342
Berry MD, Gainetdinov RR, Hoener MC, Shahid M (2017) Pharmacology of human trace amine-associated receptors: Therapeutic opportunities and challenges. Pharmacol Ther 180:161–180. https://doi.org/10.1016/j.pharmthera.2017.07.002
Revel FG, Moreau JL, Gainetdinov RR, Bradaia A, Sotnikova TD, Mory R, Durkin S, Zbinden KG, Norcross R, Meyer CA, Metzler V, Chaboz S, Ozmen L, Trube G, Pouzet B, Bettler B, Caron MG, Wettstein JG, Hoener MC (2011) TAAR1 activation modulates monoaminergic neurotransmission, preventing hyperdopaminergic and hypoglutamatergic activity. Proc Natl Acad Sci USA 108:8485–8490. https://doi.org/10.1073/pnas.1103029108
Lindemann L, Meyer CA, Jeanneau K, Bradaia A, Ozmen L, Bluethmann H, Bettler B, Wettstein JG, Borroni E, Moreau JL, Hoener MC (2008) Trace amine-associated receptor 1 modulates dopaminergic activity. J Pharmacol Exp Ther 324:948–956. https://doi.org/10.1124/jpet.107.132647
Espinoza S, Lignani G, Caffino L, Maggi S, Sukhanov I, Leo D, Mus L, Emanuele M, Ronzitti G, Harmeier A, Medrihan L, Sotnikova TD, Chieregatti E, Hoener MC, Benfenati F, Tucci V, Fumagalli F, Gainetdinov RR (2015) TAAR1 Modulates Cortical Glutamate NMDA Receptor Function. Neuropsychopharmacology 40:2217–2227. https://doi.org/10.1038/npp.2015.65
Sukhanov I, Caffino L, Efimova E V., Espinoza S, Sotnikova TD, Cervo L, Fumagalli F, Gainetdinov RR (2016) Increased context-dependent conditioning to amphetamine in mice lacking TAAR1. Pharmacol Res 103:206–214. https://doi.org/10.1016/j.phrs.2015.11.002
Revel FG, Moreau JL, Pouzet B, Mory R, Bradaia A, Buchy D, Metzler V, Chaboz S, Groebke Zbinden K, Galley G, Norcross RD, Tuerck D, Bruns A, Morairty SR, Kilduff TS, Wallace TL, Risterucci C, Wettstein JG, Hoener MC (2013) A new perspective for schizophrenia: TAAR1 agonists reveal antipsychotic- and antidepressant-like activity, improve cognition and control body weight. Mol Psychiatry 18:543–556. https://doi.org/10.1038/mp.2012.57
John J, Kukshal P, Bhatia T, Chowdari K V., Nimgaonkar VL, Deshpande SN, Thelma BK (2017) Possible role of rare variants in Trace amine associated receptor 1 in schizophrenia. Schizophr Res 189:190–195. https://doi.org/10.1016/j.schres.2017.02.020
di Cara B, Maggio R, Aloisi G, Rivet JM, Lundius EG, Yoshitake T, Svenningsson P, Brocco M, Gobert A, de Groote L, Cistarelli L, Veiga S, de Montrion CD, Rodriguez M, Galizzi JP, Lockhart BP, Cogé F, Boutin JA, Vayer P, Verdouw PM, Groenink L, Millan MJ (2011) Genetic deletion of trace amine 1 receptors reveals their role in auto-inhibiting the actions of ecstasy (MDMA). J Neurosci 31:16928–16940. https://doi.org/10.1523/JNEUROSCI.2502-11.2011
Dedic N, Jones PG, Hopkins SC, Lew R, Shao L, Campbell JE, Spear KL, Large TH, Campbell UC, Hanania T, Leahy E, Koblan KS (2019) SEP-363856, a novel psychotropic agent with a unique, non-D2 receptor mechanism of action. J Pharmacol Exp Ther 371:1–14. https://doi.org/10.1124/jpet.119.260281
Koblan KS, Kent J, Hopkins SC, Krystal JH, Cheng H, Goldman R, Loebel A (2020) A Non–D2-Receptor-Binding Drug for the Treatment of Schizophrenia. N Engl J Med 382:1497–1506. https://doi.org/10.1056/nejmoa1911772
Gainetdinov RR, Hoener MC, Berry MD (2018) Trace amines and their receptors. Pharmacol Rev 70:549–620. https://doi.org/10.1124/pr.117.015305
Revel FG, Meyer CA, Bradaia A, Jeanneau K, Calcagno E, André CB, Haenggi M, Miss MT, Galley G, Norcross RD, Invernizzi RW, Wettstein JG, Moreau JL, Hoener MC (2012) Brain-specific overexpression of trace amine-associated receptor 1 alters monoaminergic neurotransmission and decreases sensitivity to amphetamine. Neuropsychopharmacology 37:2580–2592. https://doi.org/10.1038/npp.2012.109
Rutigliano G, Accorroni A, Zucchi R (2018) The case for TAAR1 as a modulator of central nervous system function. Front Pharmacol 8:987. https://doi.org/10.3389/fphar.2017.00987
Corripio I, Escartí MJ, Portella MJ, Pérez V, Grasa E, Sauras RB, Alonso A, Safont G, Camacho MV, Dueñas R, Arranz B, San L, Catafau AM, Carrió I, Álvarez E (2011) Density of striatal D2 receptors in untreated first-episode psychosis: an I 123-IBZM SPECT study. Eur Neuropsychopharmacol 21:861–866. https://doi.org/10.1016/j.euroneuro.2011.03.004
Polyakova NV, Vinogradova EP, Aleksandrov AA, Gainetdinov RR. (2018). Prepulse inhibition in the TAAR1 knockout mice. Rossiiskii fiziologicheskii zhurnal imeni I.M. Sechenova / Rossiiskaia akademiia nauk 104:1098–1105. https://doi.org/10.1016/j.brainres.2011.04.010
Xia L, Wang D, Wang J, Xu H, Huo L, Tian Y, Dai Q, Wei S, Wang W, Zhang G, Du X, Jia Q, Zhu X, Wang L, Tang W, Zhang XY (2020) Association of cognitive and P50 suppression deficits in chronic patients with schizophrenia. Clin Neurophysiol 131:725–733. https://doi.org/10.1016/j.clinph.2019.12.405
Javitt DC, Freedman R (2015) Sensory processing dysfunction in the personal experience and neuronal machinery of schizophrenia. Am J Psychiatry 172:17–31. https://doi.org/10.1176/appi.ajp.2014.13121691
Freedman R, Waldo M, Bickford-Wimer P, Nagamoto H (1991) Elementary neuronal dysfunctions in schizophrenia. Schizophr Res 4:233–243. https://doi.org/10.1016/0920-9964(91)90035-P
Aleksandrov AA, Dmitrieva ES, Volnova AB, Knyazeva VM, Polyakova NV, Ptukha MA, Gainetdinov RR (2019) Effect of alpha-NETA on auditory event related potentials in sensory gating study paradigm in mice. Neurosci Lett 712:134470. https://doi.org/10.1016/j.neulet.2019.134470
Roger C, Hasbroucq T, Rabat A, Vidal F, Burle B (2009) Neurophysics of temporal discrimination in the rat: A mismatch negativity study. Psychophysiology 46:1028–1032. https://doi.org/10.1111/j.1469-8986.2009.00840.x
Rentzsch J, Jockers-Scherübl MC, Boutros NN, Gallinat J (2008) Test-retest reliability of P50, N100 and P200 auditory sensory gating in healthy subjects. Int J Psychophysiol 67:81–90. https://doi.org/10.1016/j.ijpsycho.2007.10.006
Mears RP, Klein AC, Cromwell HC. Auditory inhibitory gating in medial pre-frontal cortex: Single unit and local field potential analysis. Neuroscience 2006; 141 (1): 47–65. https://doi.org/10.1016/j.neuroscience.2006.03.040
Boutros NN, Korzyukov O, Jansen B, Feingold A, Bell M (2004) Sensory gating deficits during the mid-latency phase of information processing in medicated schizophrenia patients. Psychiatry Res 126:203–215. https://doi.org/10.1016/j.psychres.2004.01.007
Karkal R, Goyal N, Tikka SK, Khanande R V., Kakunje A, Khess CRJ (2018) Sensory gating deficits and their clinical correlates in drug-free/drug-naive patients with schizophrenia. Indian J Psychol Med 40:247–256. https://doi.org/10.4103/IJPSYM.IJPSYM_53_18
Clementz BA, Blumenfeld LD, Cobb S (1997) The gamma band response may account for poor P50 suppression in schizophrenia. Neuroreport 8:3889–3893. https://doi.org/10.1097/00001756-199712220-00010
Freedman R, Adler LE, Waldo MC, Pachtman E, Franks RD (1983) Neurophysiological evidence for a defect in inhibitory pathways in schizophrenia: comparison of medicated and drug-free patients. Biol Psychiatry 18(5):537-551.
Freedman R, Adler LE, Gerhardt GA, Waldo M, Baker N, Rose GM, Drebing C, Nagamoto H, Bickford-Wimer P, Franks R. (1987) Neurobiological studies of sensory gating in schizophrenia. Schizophr Bull. 13(4):669-678. https://doi.org/10.1093/schbul/13.4.669.